Arnhold LLC reduced its position in shares of Curis, Inc. (NASDAQ:CRIS – Free Report) by 7.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,348 shares of the biotechnology company’s stock after selling 1,302 shares during the period. Arnhold LLC owned approximately 0.28% of Curis worth $208,000 as of its most recent filing with the Securities and Exchange Commission.
Wall Street Analyst Weigh In
Separately, HC Wainwright cut their target price on Curis from $51.00 to $26.00 and set a “buy” rating on the stock in a report on Friday, February 9th.
Read Our Latest Research Report on Curis
Curis Stock Performance
Curis (NASDAQ:CRIS – Get Free Report) last posted its quarterly earnings data on Thursday, February 8th. The biotechnology company reported ($2.03) EPS for the quarter, missing the consensus estimate of ($1.91) by ($0.12). Curis had a negative net margin of 473.04% and a negative return on equity of 169.22%. The firm had revenue of $2.70 million during the quarter, compared to analysts’ expectations of $2.95 million. During the same quarter in the previous year, the company posted ($2.40) EPS. As a group, sell-side analysts anticipate that Curis, Inc. will post -5.92 earnings per share for the current fiscal year.
About Curis
Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
Recommended Stories
- Five stocks we like better than Curis
- What Is WallStreetBets and What Stocks Are They Targeting?
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Hilton Demonstrates Asset Light is Right for Investors
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Want to see what other hedge funds are holding CRIS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Curis, Inc. (NASDAQ:CRIS – Free Report).
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.